Collegium Pharmaceutical (COLL) Interest & Investment Income (2014 - 2026)

Collegium Pharmaceutical has reported Interest & Investment Income for 13 years, with the latest figure at $2.3 million in Q2 2026.

• On a quarterly basis, Interest & Investment Income fell 3.94% year-over-year to $2.3 million in Q2 2026; TTM through Jun 2026 was $12.7 million, a 30.68% increase from a year earlier, with the FY2025 full-year figure at $11.3 million, down 19.23% from the prior year.
• Interest & Investment Income was $2.3 million for Q2 2026 at Collegium Pharmaceutical, down from $3.7 million in the prior quarter.
• The five-year high for Interest & Investment Income was $4.5 million in Q3 2023, with the low at $4000.0 in Q1 2022.
• Average Interest & Investment Income over 5 years is $2.7 million, with a median of $2.9 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Interest & Investment Income jumped 80440.0% in 2023, then slumped 57.89% in 2024.
• Over 5 years, Interest & Investment Income stood at $1.0 million in 2022, then jumped by 318.99% to $4.3 million in 2023, then plunged by 57.89% to $1.8 million in 2024, then jumped by 96.74% to $3.6 million in 2025, then tumbled by 35.79% to $2.3 million in 2026.
• The last three Interest & Investment Income figures came in at $2.3 million (Q2 2026), $3.7 million (Q1 2026), and $3.6 million (Q4 2025), per Business Quant data.